| Bioactivity | DprE1-IN-9 (compound B18) is an effective reversible DprE1 inhibitor and can bind to the receptor cavity of DprE1. DprE1-IN-9 shows strong antimycobacterial activity not only against non-pathogenic strain H37Ra (MIC=0.18 µg/mL) but also against pathogenic H37Rv and the clinical MDR and XDR isolates[1]. |
| Name | DprE1-IN-9 |
| CAS | 2906099-98-5 |
| Formula | C22H25F3N4O2 |
| Molar Mass | 434.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Xiang, et al. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis. Microbiol Spectr. 2023 Sep 12:e0472122. |
DprE1-IN-9
CAS: 2906099-98-5 F: C22H25F3N4O2 W: 434.45
DprE1-IN-9 (compound B18) is an effective reversible DprE1 inhibitor and can bind to the receptor cavity of DprE1. DprE1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.